Shots:
- Sanofi has signed an exclusive worldwide licensing agreement with C4XD worth up to $492.94M million, for C4XD’s oral pre-clinical IL-17A inhibitor program
- C4XD to receive $8.33M up front and is eligible to receive up to $484.60M as development, regulatory and commercial milestones including $13.09M as pre-clinical milestones along with royalties
- Sanofi will develop and commercialize an oral therapy for inflammatory diseases and will continue to work with the C4XD team to access its 4D Conformetrix technology, following the advancement of the program towards clinical studies
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Sanofi
The post Sanofi Collaborates with C4XD for an Oral Therapy to Treat Inflammatory Diseases first appeared on PharmaShots.
